Real-World Evaluation of the Natural History and Long-Term Clinical Effects of GLP-1 and GLP-1/GIP Therapies in US Adults Living With Obesity: REFLECT US

20/11/2026
20/11/2026
EU PAS number:
EUPAS1000001167
Study
Planned
Study type

Study topic

Disease /health condition
Human medicinal product

Study type

Non-interventional study

Scope of the study

Disease epidemiology
Drug utilisation
Effectiveness study (incl. comparative)
Healthcare resource utilisation
Safety study (incl. comparative)

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Medicinal product name

Medicinal product name, other

Semaglutide
Tirzepatide

Medical condition to be studied

Obesity
Population studied

Short description of the study population

Participants will be defined by body mass index (BMI), type 2 diabetes mellitus (T2DM), cardiometabolic comorbidities, and treatment with glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) at index.

Participants must meet protocol-defined inclusion and exclusion criteria during at least 1 outpatient visit that occurred between January 1, 2018, and June 30, 2024.

Age groups

  • Adult and elderly population (≥18 years)
    • Adults (18 to < 65 years)
      • Adults (18 to < 46 years)
      • Adults (46 to < 65 years)
    • Elderly (≥ 65 years)
      • Adults (65 to < 75 years)
      • Adults (75 to < 85 years)
      • Adults (85 years and over)

Estimated number of subjects

8.780.022
Study design details

Study design

K9531-5101-US is a retrospective observational cohort study designed to characterise the natural history, treatment patterns, clinical outcomes, and healthcare resource utilisation of adults living with obesity in the United States (US).

Main study objective

K9531-5101-US will evaluate the natural history of obesity in the US using longitudinal real-world healthcare data. The study is intended to provide context regarding participant characteristics, disease burden, treatment patterns, clinical outcomes, and healthcare utilisation among adults living with obesity in routine clinical practice.

A random index date will be assigned to each qualifying participant from eligible visit dates, requiring at least 12 months of prior data to assess eligibility. Newly qualifying participants in subsequent years will receive an index date within their first year of eligibility. Baseline characteristics will be assessed at the index date, with follow-up to evaluate changes and prespecified outcomes.

The study will also provide real-world evidence on obesity and obesity management in routine clinical practice and support the design of 4 prospective cohorts intended to mirror the following three Phase 3 registrational, randomized, double-blinded, placebo-controlled trials that are currently investigating the effects of ribupatide compared with placebo and semaglutide: K9531-3103 (NCT07284875), K9531-3104 (NCT07284901), and K9531-3107 (NCT07284979).

Retrospective observational cohort studies of the natural history of obesity will also be conducted in the United Kingdon (UK) (K9531-5102-UK [REFLECT UK]) and in Spain (K9531-5103-ESP [REFLECT Spain]).

Setting

Key Inclusion Criteria:

Cohort 1:
• BMI ≥30 kilograms/square metre (kg/m^2) on at least 2 visits or
• BMI ≥27 to <30 kg/m^2 on at least 2 visits and previously diagnosed with at least 1 of the following the year before the second BMI ≥27 to <30 kg/m^2 visit: hypertension; dyslipidemia; obstructive sleep apnoea; ischemic cardiovascular disease

Cohort 2:
• BMI ≥27 kg/m^2 on at least 2 visits
• Diagnosis of T2DM the year before the second BMI ≥27 kg/m^2 visit

Cohort 3:
• BMI ≥35 kg/m^2 on at least 2 visits

Cohort 4:
• BMI ≥35 kg/m^2 on at least 2 visits
• At least 1 filled semaglutide prescription

Key Exclusion Criteria:

Cohorts 1, 3, and 4:
• History of type 1 diabetes mellitus (T1DM) or T2DM
• One-year pre-index history of T1DM, T2DM, diabetic ketoacidosis or hyperosmolar state/coma
• One-year pre-index laboratory evidence of diabetes mellitus (DM) including haemoglobin A1c ≥6.5%, fasting glucose ≥126 milligrams/decilitre (mg/dL), or random glucose or 2-hour glucose measurement from a 2-hour oral glucose tolerance test ≥200 mg/dL

Cohort 2 (history of T2DM is inclusion criterion):
• One-year pre-index history of T1DM, DM due to underlying condition, drug or chemical induced DM, other specified, diabetic ketoacidosis or hyperosmolar state/coma
• One-year pre-index history of T2DM with hypoglycaemia with coma or T2DM with hypoglycaemia without coma and use of hypoglycaemia treatment

All Cohorts:
• Three-month pre-index initiation of medications strongly associated with weight gain
• One-year chronic treatment with medications that strongly affect gastrointestinal motility
• One-year pre-index diagnosis of multiple endocrine neoplasia Type 2 or medullary thyroid cancer
• One-year pre-index diagnosis of chronic or acute pancreatitis
• One-year pre-index diagnosis of gastric-emptying abnormalities
• One-year pre-index diagnosis of severe major depressive disorder/episode and disruptive mood disorders

Note: Other protocol-specified criteria may apply.

Outcomes

Primary Outcomes:
1. Percentage Change from Index Date in Body Weight

Secondary Outcomes:
2. Number of Participants with Obesity Per 1,000 Patient Years
3. Participant Age
4. Participant Sex
5. Participant Race
6. Participant Ethnicity
7. Participant Weight
8. Number of Participants Admitted to the Hospital
9. Length of Inpatient Hospital Stay (Days)
10. Number of Outpatient Visits
11. Annual Healthcare Cost
12. Change from Index Date in Body Weight
13. Change from Index Date in Systolic Blood Pressure and Diastolic Blood Pressure
14. Time from Index Date to Death (All Cause)
15. Number of Participants Admitted to the Hospital
16. Length of Inpatient Hospital Stay (Days)
17. Number of Outpatient Visits
18. Annual Healthcare Cost
19. Number of Participants Initiating GLP-1 or GLP-1/GIP by 6-month Intervals
20. Number of Participants Permanently Discontinuing GLP-1 or GLP-1/GIP by 6-month Intervals
21. Systolic Blood Pressure and Diastolic Blood Pressure in the Intention-to-treat (ITT) and Per-protocol (PP) Subgroups at Index
22. Percentage Change in Body Weight in ITT and PP Subgroups
23. Time from Index Date to Death (All Cause) for ITT and PP Subgroups
24. Number of Participants Admitted to the Hospital for ITT and PP Subgroups
25. Length of Inpatient Hospital Stay (Days) for ITT and PP Subgroups
26. Number of Outpatient Visits for ITT and PP Subgroups
27. Annual Healthcare Cost for ITT and PP Subgroups
28. Systolic Blood Pressure and Diastolic Blood Pressure in Age Subgroups
29. Percentage Change in Body Weight by Age Subgroups
30. Time From Index Date to Death (All Cause) in Age Subgroups
31. Number of Participants Admitted to the Hospital for Age Subgroups
32. Length of Inpatient Hospital Stay (Days) for Age Subgroups
33. Number of Outpatient Visits for Age Subgroups
34. Annual Healthcare Cost for Age Subgroups